Dr. Kirschbaum joined Cyclacel as Senior Vice President and Chief Medical Officer in October 2020. Dr. Kirschbaum is a highly experienced hematologist/oncologist with over 30 years of experience in molecular medicine, new drug development, clinical trial design and patient care. He has management experience in both academic research and clinical and pharmaceutical settings. He served as Vice President, Hematology/ Oncology at ArQule Inc., where he managed the development of their BTK inhibitor ARQ531 for hematological indications, including CLL. Previously, he was Senior Medical Director with global clinical development responsibilities at Daiichi-Sankyo, Taiho Pharmaceuticals and BeiGene, USA, where he led the clinical development of novel compounds in various solid tumors and hematological malignancies. Dr. Kirschbaum has also served as Professor of Medicine, Director of Experimental Therapeutics, Hematology at the Monter Cancer Center/NSLIJHS; Professor of Medicine, Director Hematologic Malignancies at Penn State, Hershey Cancer Center; Director of Experimental Therapeutics, Nevada Cancer Institute; Director, New Drug Development at the City of Hope National Cancer Center, and Attending Senior Physician, Department of Hematology and Department of Bone Marrow Transplantation, Tel Aviv Sourasky Medical Center. He earned a B.A. from Yeshiva Univ
Current role
SVP, Chief Medical Officer at Cytokinetics
SVP & Chief Medical Officer at Yale New Haven Health
SVP, Chief Medical Officer at Telecare Corporation
SVP & Chief Medical Officer, Acute Care at Array Behavioral Care
SVP & Chief Medical Officer, Chief of Psychiatry, Care New England at Butler Hospital
Access the worlds's biggest network of public org charts
Learn more